Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
The efficiency of a new prothrombin-based activated protein C (APC) resistance test to detect factor V Leiden (FVL) was clinically evaluated in 150 Italian patients with deep venous thrombosis. Patient samples are diluted in factor-V-deficient plasma, an APC-containing reagent, and specific factor V activator; after incubation, clotting is initiated by addition of activated-factor-FV-dependent prothrombin activator. Two prothrombin time determinations were performed under identical assay conditions except that no APC was added to one. A ratio over 4.2 for normal individuals and under 2.0 for FVL patients is expected: between 1.3 and 1.9 for FVL heterozygotes, and between 1.0 and 1.1 for FVL homozygotes. Using a predefined cut-off ratio of 2.0, a specificity and a sensitivity of 1.00 for detection of FVL mutation were found. With a cut-off ratio of 1.1, a specificity of 0.98 and a sensitivity of 1.00 were found for discrimination between FVL heterozygous (n = 60) and homozygous (n = 6). No interferences by heparins, oral contraceptives, oral anticoagulant therapy, protein C, protein S, D-dimer, homocysteine, MTHFR mutations and antiphospholipid autoantibodies were detected. In our experience, this new prothrombin time-based APC resistance assay provides improved discrimination between normal individuals and FVL carriers compared with the classical methods. Moreover, this new assay allows good discrimination between homozygous and heterozygous FVL carriers. In the authors' experience this prothrombin time-based method was not influenced by many factors compared with the classical activated partial thromboplastin time-based method.
Gessoni
Gianluca
G
Clinical Pathology Laboratory, Ospedale Civile, Chioggia, Venice, Italy. gessoni@asl14chioggia.veneto.it
Valverde
Sara
S
D020016:Activated Protein C Resistance / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism*; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005165:Factor V / Q000032:analysis / Q000235:genetics* / Q000378:metabolism*; D005240:Feasibility Studies; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011486:Protein C / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D011517:Prothrombin Time / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D019851:Thrombophilia / Q000175:diagnosis / Q000235:genetics; D020246:Venous Thrombosis / Q000175:diagnosis* / Q000235:genetics* / Q000378:metabolism
D011486:Protein C; D005165:Factor V; D011516:Prothrombin